Viome Life Sciences, founded in 2016, is a precision health company focused on the prevention, early diagnosis, and treatment of chronic diseases and cancer. It works by digitising and interpreting human biology at the molecular level, combining microbiome analysis with human gene expression (mRNA transcriptomics) to generate individualised health insights.
The company's flagship offering is what it describes as the industry's only direct-to-consumer healthcare test that analyses both microbial and human mRNA gene expression simultaneously. Test results feed into a proprietary AI platform trained on data from over 600,000 biological samples, which produces personalised dietary recommendations and precision supplements tailored to an individual's biological profile. Viome's analytical framework draws on three layers: AI-driven models, biological data interpretation, and clinical or expert input.
Viome operates across several intersecting technical domains, including:
- Microbiome and transcriptomic analysis
- Machine learning and large-scale biological data science
- Direct-to-consumer diagnostics
- Precision nutrition and nutraceutical formulation
The company is founder-led by CEO Naveen Jain, with a stated mission to extend disease-free human lifespan by making chronic disease preventable rather than merely treatable. Its work sits at the intersection of consumer health, diagnostics, and applied life sciences research.
